OM:ARCOMA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Arcoma AB develops, produces, and provides radiology solutions worldwide. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Arcoma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ARCOMA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

ARCOMA

1.4%

SE Medical Equipment

2.4%

SE Market


1 Year Return

-4.6%

ARCOMA

19.3%

SE Medical Equipment

17.0%

SE Market

Return vs Industry: ARCOMA underperformed the Swedish Medical Equipment industry which returned 20.5% over the past year.

Return vs Market: ARCOMA underperformed the Swedish Market which returned 16.4% over the past year.


Shareholder returns

ARCOMAIndustryMarket
7 Day0%1.4%2.4%
30 Day11.6%2.3%4.5%
90 Day-0.5%15.1%13.0%
1 Year-4.6%-4.6%21.3%19.3%19.0%17.0%
3 Year174.3%174.3%70.8%50.7%37.5%22.8%
5 Year234.7%234.7%99.5%66.0%75.8%41.3%

Price Volatility Vs. Market

How volatile is Arcoma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Arcoma undervalued compared to its fair value and its price relative to the market?

24.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ARCOMA (SEK19.75) is trading below our estimate of fair value (SEK26.16)

Significantly Below Fair Value: ARCOMA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ARCOMA is good value based on its PE Ratio (25.8x) compared to the SE Medical Equipment industry average (34.6x).

PE vs Market: ARCOMA is poor value based on its PE Ratio (25.8x) compared to the Swedish market (22.1x).


Price to Earnings Growth Ratio

PEG Ratio: ARCOMA is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: ARCOMA's PB Ratio (4.8x) is in line with the SE Medical Equipment industry average.


Next Steps

Future Growth

How is Arcoma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

32.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARCOMA's forecast earnings growth (32.4% per year) is above the savings rate (0.5%).

Earnings vs Market: ARCOMA's earnings (32.4% per year) are forecast to grow faster than the Swedish market (15.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ARCOMA's revenue (19.9% per year) is forecast to grow faster than the Swedish market (3.8% per year).

High Growth Revenue: ARCOMA's revenue (19.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ARCOMA's Return on Equity is forecast to be high in 3 years time (20.1%)


Next Steps

Past Performance

How has Arcoma performed over the past 5 years?

53.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ARCOMA has high quality earnings.

Growing Profit Margin: ARCOMA's current net profit margins (7.5%) are higher than last year (1.9%).


Past Earnings Growth Analysis

Earnings Trend: ARCOMA has become profitable over the past 5 years, growing earnings by 53.8% per year.

Accelerating Growth: ARCOMA's earnings growth over the past year (287.3%) exceeds its 5-year average (53.8% per year).

Earnings vs Industry: ARCOMA earnings growth over the past year (287.3%) exceeded the Medical Equipment industry 17.2%.


Return on Equity

High ROE: ARCOMA's Return on Equity (18.6%) is considered low.


Next Steps

Financial Health

How is Arcoma's financial position?


Financial Position Analysis

Short Term Liabilities: ARCOMA's short term assets (SEK49.0M) exceed its short term liabilities (SEK30.3M).

Long Term Liabilities: ARCOMA's short term assets (SEK49.0M) exceed its long term liabilities (SEK2.9M).


Debt to Equity History and Analysis

Debt Level: ARCOMA's debt to equity ratio (20.3%) is considered satisfactory.

Reducing Debt: ARCOMA's debt to equity ratio has reduced from 33.7% to 20.3% over the past 5 years.

Debt Coverage: ARCOMA's debt is well covered by operating cash flow (186.7%).

Interest Coverage: ARCOMA's interest payments on its debt are well covered by EBIT (22.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Arcoma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ARCOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARCOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ARCOMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARCOMA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ARCOMA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average board tenure


CEO

Arcoma has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Mats Thoren
Director8.67yrskr58.00k5.21%
SEK 13.2m
Anders Dahlberg
Director2.67yrskr58.00kno data
Lars Kvarnhem
Chairman3.67yrskr400.00kno data
Jesper Söderqvist
Director0.25yrno data0.20%
SEK 493.8k

3.2yrs

Average Tenure

48.5yo

Average Age

Experienced Board: ARCOMA's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Arcoma AB's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arcoma AB
  • Ticker: ARCOMA
  • Exchange: OM
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr252.405m
  • Shares outstanding: 12.78m
  • Website: https://www.arcoma.se

Number of Employees


Location

  • Arcoma AB
  • Annavägen 1
  • Växjö
  • Kronoberg County
  • 352 46
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARCOMAOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKNov 2014

Biography

Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skelet ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 02:54
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.